Evgen Pharma PLC Research Collaboration with Imperial College (2047I)
March 20 2018 - 3:00AM
UK Regulatory
TIDMEVG
RNS Number : 2047I
Evgen Pharma PLC
20 March 2018
For immediate release 20 March 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Research collaboration with Imperial College
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce a new research collaboration
with Imperial College London ("Imperial") focusing on the mechanism
of action in a number of diseases of SFX-01, the Company's lead
product candidate.
The project is being funded principally by an Engineering and
Physical Sciences Research Council Impact Acceleration Account
grant and will be led by Professor Ed Tate, whose research
interests at Imperial include chemical proteomics, medicinal
chemistry and drug discovery. Evgen Pharma will supply SFX-01 and
make a modest financial contribution.
The objective of the collaboration is to use advanced chemical
proteomics technology to detect targets for SFX-01 and other
sulforaphane analogues in live cells or tissues in specific disease
model systems. This would provide greater understanding of
mechanism(s) of action and contribute data important for current
and future clinical development.
In 2017, Professor Ed Tate's research group published a
scientific paper(*) identifying STAT3 as a direct binding target of
sulforaphane, the active principle of SFX-01. On 15 January 2018,
the Company announced that SFX-01 potently suppressed activated
STAT3 in patient-derived tumours treated with endocrine treatment,
which may explain how SFX-01 reverses the resistance to hormone
treatment seen in oestrogen-receptor positive ("ER+") breast
cancers.
As part of the agreement, Imperial will negotiate an exclusive
licence giving Evgen Pharma rights to exploit any intellectual
property resulting from the research collaboration.
Professor Ed Tate, Professor of Chemical Biology, Imperial
College London, commented:
"We are delighted to be collaborating with Evgen Pharma on this
exciting project, which will build on the work that we at Imperial
published last year on the first comprehensive and quantitative
system-level analysis of the direct targets of sulforaphane in
breast cancer cell lines."
Steve Franklin, CEO of Evgen Pharma, said:
"We welcome the opportunity to work with Professor Tate whose
innovations in the field of chemical proteomics provide the
opportunity to improve our knowledge of SFX-01's mechanism of
action in cancer and neurology. Meanwhile, we look forward to our
first Phase II clinical data from SFX-01 in breast cancer in the
first half of this year, when we will announce the interim readout
from our ongoing STEM trial."
(*) Clulow et al. (2017) Competition-based quantitative chemical
proteomics in breast cancer cells identifies new target profiles
for sulforaphane. Chem. Commun. 53(37): 5182-5185
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney,
Tom Price (Corporate Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCJLMRTMBTBBIP
(END) Dow Jones Newswires
March 20, 2018 03:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024